Doctor of Podiatric Medicine Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Murad Abdel-Qader

Podiatrist San Antonio, TX Doctor of Podiatric Medicine

NPI 1598700320 CMS profile 162326

88 Briggs St Ste 170, San Antonio, TX 78224

Open in the dashboard

General payments

$3,133

31 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Murad Abdel-Qader of San Antonio, TX is reported in the CMS Open Payments database as having received $3,133 across 31 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $51 2
2023 General $97 3
2022 General $1,363 8
2021 General $245 8
2020 General $45 2
2019 General $1,332 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Murad Abdel-Qader
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Murad Abdel-Qader were reported at $0. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Murad Abdel-Qader Podiatrist median Middle half National median
2019 $1,332 $196 $72–$601 $163
2020 $45 $118 $38–$335 $114
2021 $245 $169 $57–$573 $132
2022 $1,363 $220 $74–$782 $149
2023 $97 $208 $71–$635 $160
2024 $51 $237 $87–$681 $164
2025 $0 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Pylant Medical $2,315 2 payments
  2. Stryker Corporation $595 18 payments
  3. Integra LifeSciences Corporation $47 1 payment
  4. Sebela Pharmaceuticals Inc. $45 3 payments
  5. Organogenesis Inc. $27 1 payment
  6. Wright Medical Technology, Inc. $25 1 payment
  7. Globus Medical, Inc. $21 1 payment
  8. Treace Medical Concepts, Inc. $17 1 payment
  9. Tactile Systems Technology Inc $16 1 payment
  10. GRT US Holding, Inc. $14 1 payment
  11. Other $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Education $2,315 2 payments
  2. Food and Beverage $818 29 payments
Products named General payments · program years 2019–2024
  1. BIO4 $141 1 payment
  2. ANCHORAGE $118 2 payments
  3. ORTHOLOC 3DI $64 2 payments
  4. ASNIS $63 3 payments
  5. ORTHOLOC 2 LAPIFUSE $51 1 payment
  6. AMNIOEXCEL $47 1 payment
  7. BILAYER WOUND MATRIX (BWM) $47 1 payment
  8. INTEGRA WOUND MATRIX (IWM) $47 1 payment
  9. IDRT $47 1 payment
  10. FLOWABLE $47 1 payment
  11. Other $407 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

469

Median for Podiatry: 160

Drug cost

$7,774

Median for Podiatry: $2,368

Branded share of claims

12.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 136 $4,734
Ammonium Lactate Generic 94 $1,455
Gabapentin Generic 45 $408
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 48 $367
Cephalexin Generic 38 $295
Ciprofloxacin Hcl Generic 25 $160
Ibuprofen Generic 31 $142
Hydrocortisone Generic 15 $117
Terbinafine Hcl Generic 14 $47
Amoxicillin Generic 12 $27

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$90,421

Medicare's payments for the services billed

Medicare patients

200

Average age 73

Services billed

1,727

101 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 72%
Arthritis 54%
Chronic kidney disease 40%
Ischemic heart disease 36%
Heart failure 25%
Depression 25%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

31 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record